Clinical trials: Optic Neuritis
Optic Neuritis
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
Patients aged between 18 and 70 with acute aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) positive optic neuritis, irrespective of prior using of corticosteroids in this episode of disease, are chosen by the physician.
- Trial name
- NCT03586557
- Testing
- Corticosteroid & Plasma exchange, Corticosteroid
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Chinese PLA General Hospital
Optic Neuritis
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
This will be a hospital-based retrospective multi-center study on epidemiologic and clinical characteristics of optic neuritis among Chinese. The investigation will cover about 29 provinces or municipalities all around China.
- Trial name
- NCT04257734
- Testing
- observation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chinese PLA General Hospital
Optic Neuritis, Multiple Sclerosis
The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS
Disruption of the blood brain barrier (BBB) is associated with inflammatory conditions of the central nervous system (CNS). This clinical trial aims to investigate whether following a gluten-free diet (GFD) for six months can…
- Conditions
- Optic Neuritis, Multiple Sclerosis, Clinically Isolated Syndrome
- Trial name
- NCT03451955
- Testing
- Gluten-free diet
- Where
- 2 sites in Denmark
- Volunteers
- 103 people
- Sponsor
- University of Copenhagen
Optic Neuritis
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation…
- Trial name
- ReCOVER (NCT02521311)
- Testing
- Clemastine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of California, San Francisco
Neuromyelitis Optica Spectrum Disorders
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06068829
- Testing
- Inebilizumab, Rituximab(RTX)
- Volunteers
- 80 people
- Sponsor
- Feng Jinzhou
Ischemic Optic Neuropathy, Optic Neuritis
Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.
The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging
- Conditions
- Ischemic Optic Neuropathy, Optic Neuritis, Compressive Optic Neuropathy, Traumatic Optic Neuropathy
- Trial name
- NCT05353413
- Testing
- Neuroimaging, VEP - visual evoked potential, Ophthalmology examination.
- Where
- Poland
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men.
- Trial name
- NCT03401879
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis, Neuromyelitis Optica
Immunologic Biomarker Profile of Cerebrospinal Fluid
The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal fluid in multiple sclerosis patients
- Trial name
- BIOMOG (NCT04202055)
- Testing
- Biomarker analysis
- Where
- France
- Volunteers
- 165 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis
Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)
Hypothesis: Intravenous administration of bone marrow-derived autologous adult human mesenchymal stem cells is a safe novel therapeutic approach for patients with multiple sclerosis.
- Trial name
- MSCIMS (NCT00395200)
- Testing
- MSC Treatment
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Cambridge
Neuromyelitis Optica Spectrum Disorder Attack
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage.
- Trial name
- ETA/PETA-NMOSD (NCT07410039)
- Testing
- Eculizumab+IVMP, IVIG+IVMP, IVMP
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorders
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
- Trial name
- NCT06413654
- Testing
- B001
- Where
- 51 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Optic Neuritis
Edaravone in the Treatment of Optic Neuritis
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive…
- Trial name
- NCT05540262
- Testing
- Edaravone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Optic Neuritis
Interest of Dynamic Measures of the Pupil in Optic Neuritis
The investigators' hypothesis is that measuring the PCTdynamics would be an easy and reliable symptom to evaluate in pathologies affecting the optic nerve
- Trial name
- PCT-NORB (NCT02004054)
- Testing
- measure of pupil diameter
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neuromyelitis Optica Spectrum Disorder
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD) are a group of inflammatory demyelinating disorders of the central nervous system.
- Trial name
- NCT03819413
- Testing
- serum aquaporin 4 antibody (AQP-4-Ab), serum MOG antibody (anti-MOG), MRI brain, spine and orbit
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Assiut University
Multiple Sclerosis, Optic Neuritis
Optical Coherence Tomography in Multiple Sclerosis Patients
To evaluate the ability of different spectral domain optical coherence tomography (OCT) devices, as well as different acquisition and analysis packages, to detect disease progression in patients with multiple sclerosis with and…
- Trial name
- NCT01774123
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorders (NMOSD) is characterized by the pathogenic anti-AQP4 antibody, which can be produced by specific plasma cells.
- Trial name
- NCT02893111
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
To investigate multimodel MRI exploring the pathophysiology of multiple sclerosis and neuromyelitis optica spectrum disorders. The investigators use multimodel MRI to evaluate the extent of blood-brain barrier and white matter…
- Trial name
- NCT02836327
- Testing
- Magnetic Resonance Imaging
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Optic Neuritis, Optic; Neuritis, With Demyelination
BN201 SAD MAD Study in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.
- Trial name
- NCT03630497
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Accure Therapeutics